Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Extension of the 6-month, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Comparing Efficacy and Safety of FTY720 0.5 mg and 1.25 mg Administered Orally Once Daily in Patients With Relapsing Multiple Sclerosis

NCT00670449 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00670449
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00670449 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Extension of the 6-month, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Comparing Efficacy and Safety of FTY720 0.5 mg and 1.25 mg Administered Orally Once Daily in Patients With Relapsing Multiple Sclerosis
Lead sponsor
Novartis
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2008
Completion date
April 30, 2012
Enrollment
143 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis